BidaskClub downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong-buy rating to a buy rating in a report published on Thursday.
VNDA has been the topic of a number of other reports. Zacks Investment Research cut Vanda Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Wednesday, August 8th. TheStreet upgraded Vanda Pharmaceuticals from a c rating to a b- rating in a research note on Friday, October 26th. CIBC reiterated an outperform rating on shares of Vanda Pharmaceuticals in a research note on Friday, September 21st. Stifel Nicolaus started coverage on Vanda Pharmaceuticals in a research note on Thursday, September 13th. They issued a buy rating and a $30.00 price objective on the stock. Finally, Oppenheimer set a $29.00 price objective on Vanda Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, October 3rd. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $26.86.
NASDAQ:VNDA opened at $20.46 on Thursday. Vanda Pharmaceuticals has a 52 week low of $11.90 and a 52 week high of $23.50. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of 2,046.00 and a beta of 1.06.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: Institutional Investors
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.